161 related articles for article (PubMed ID: 17072242)
1. [Use of cabergoline in persisting Cushing's disease].
Illouz F; Dubois-Ginouves S; Laboureau S; Rohmer V; Rodien P
Ann Endocrinol (Paris); 2006 Sep; 67(4):353-6. PubMed ID: 17072242
[TBL] [Abstract][Full Text] [Related]
2. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
Pivonello R; De Martino MC; Cappabianca P; De Leo M; Faggiano A; Lombardi G; Hofland LJ; Lamberts SW; Colao A
J Clin Endocrinol Metab; 2009 Jan; 94(1):223-30. PubMed ID: 18957500
[TBL] [Abstract][Full Text] [Related]
3. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
Burman P; Edén-Engström B; Ekman B; Karlsson FA; Schwarcz E; Wahlberg J
Eur J Endocrinol; 2016 Jan; 174(1):17-24. PubMed ID: 26582653
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline for Cushing's disease: A case report.
Pascual-Corrales E; Tomás Velázquez A; Zubieta JL; Salvador J; Galofré JC
Endocrinol Nutr; 2015 Dec; 62(10):516-8. PubMed ID: 26307390
[No Abstract] [Full Text] [Related]
5. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
Miyoshi T; Otsuka F; Takeda M; Inagaki K; Suzuki J; Ogura T; Date I; Hashimoto K; Makino H
J Endocrinol Invest; 2004 Dec; 27(11):1055-9. PubMed ID: 15754738
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.
Vilar L; Naves LA; Azevedo MF; Arruda MJ; Arahata CM; Moura E Silva L; Agra R; Pontes L; Montenegro L; Albuquerque JL; Canadas V
Pituitary; 2010 Jun; 13(2):123-9. PubMed ID: 19943118
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline treatment for recurrent Cushing's disease during pregnancy.
Nakhleh A; Saiegh L; Reut M; Ahmad MS; Pearl IW; Shechner C
Hormones (Athens); 2016 Jul; 15(3):453-458. PubMed ID: 27394707
[TBL] [Abstract][Full Text] [Related]
8. Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report.
Manavela MP; Danilowicz K; Bruno OD
Pituitary; 2012 Dec; 15 Suppl 1():33-6. PubMed ID: 22038028
[TBL] [Abstract][Full Text] [Related]
9. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
Shiraishi J; Koyama H; Shirakawa M; Ishikura R; Okazaki H; Kurajoh M; Shoji T; Moriwaki Y; Yamamoto T; Namba M
Intern Med; 2016; 55(8):935-41. PubMed ID: 27086808
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
Feelders RA; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; van Heerebeek R; de Jong FH; van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
N Engl J Med; 2010 May; 362(19):1846-8. PubMed ID: 20463350
[No Abstract] [Full Text] [Related]
11. Cabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere A; Cortet C; Chanson P; Delemer B; Caron P; Chabre O; Reznik Y; Bertherat J; Rohmer V; Briet C; Raingeard I; Castinetti F; Beckers A; Vroonen L; Maiter D; Cephise-Velayoudom FL; Nunes ML; Haissaguerre M; Tabarin A
Eur J Endocrinol; 2017 Mar; 176(3):305-314. PubMed ID: 28007845
[TBL] [Abstract][Full Text] [Related]
12. Remission with cabergoline in adolescent boys with Cushing's disease.
Güven A; Baltacıoğlu F; Dursun F; Cebeci AN; Kırmızıbekmez H
J Clin Res Pediatr Endocrinol; 2013 Sep; 5(3):194-8. PubMed ID: 24072089
[TBL] [Abstract][Full Text] [Related]
13. Update in the medical therapy of Cushing's disease.
Nieman LK
Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):330-4. PubMed ID: 23807605
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline monotherapy in the long-term treatment of Cushing's disease.
Godbout A; Manavela M; Danilowicz K; Beauregard H; Bruno OD; Lacroix A
Eur J Endocrinol; 2010 Nov; 163(5):709-16. PubMed ID: 20702648
[TBL] [Abstract][Full Text] [Related]
15. Pituitary-targeted medical therapy of Cushing's disease.
Alexandraki KI; Grossman AB
Expert Opin Investig Drugs; 2008 May; 17(5):669-77. PubMed ID: 18447593
[TBL] [Abstract][Full Text] [Related]
16. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
17. Cushing's disease in dogs: cabergoline treatment.
Castillo VA; Gómez NV; Lalia JC; Cabrera Blatter MF; García JD
Res Vet Sci; 2008 Aug; 85(1):26-34. PubMed ID: 17910968
[TBL] [Abstract][Full Text] [Related]
18. Use of cabergoline for the management of persistent Cushing's disease in pregnancy.
Sek KS; Deepak DS; Lee KO
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710189
[TBL] [Abstract][Full Text] [Related]
19. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
van der Pas R; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Webb SM; Lamberts SW; Hofland LJ; Feelders RA
Pituitary; 2013 Dec; 16(4):536-44. PubMed ID: 23225121
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].
Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M
Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
